GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (OTCPK:CFBFF) » Definitions » Cyclically Adjusted PS Ratio

Can Fite Biofarma (Can Fite Biofarma) Cyclically Adjusted PS Ratio : (As of May. 25, 2024)


View and export this data going back to . Start your Free Trial

What is Can Fite Biofarma Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Can Fite Biofarma Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Can Fite Biofarma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Can Fite Biofarma Cyclically Adjusted PS Ratio Chart

Can Fite Biofarma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 1.65 1.55 0.95 -

Can Fite Biofarma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 0.32 0.45 0.39 -

Competitive Comparison of Can Fite Biofarma's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Can Fite Biofarma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Can Fite Biofarma's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's Cyclically Adjusted PS Ratio falls into.



Can Fite Biofarma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Can Fite Biofarma's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Can Fite Biofarma's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.007/129.4194*129.4194
=0.007

Current CPI (Dec. 2023) = 129.4194.

Can Fite Biofarma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.000 99.695 0.000
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 0.000 99.070 0.000
201503 0.000 99.621 0.000
201506 0.003 100.684 0.004
201509 0.003 100.392 0.004
201512 0.001 99.792 0.001
201603 0.003 100.470 0.004
201606 0.003 101.688 0.004
201609 0.003 101.861 0.004
201612 0.000 101.863 0.000
201703 0.003 102.862 0.004
201706 0.003 103.349 0.004
201709 0.027 104.136 0.034
201712 0.004 104.011 0.005
201803 0.030 105.290 0.037
201806 0.013 106.317 0.016
201809 0.123 106.507 0.149
201812 0.014 105.998 0.017
201903 0.014 107.251 0.017
201906 0.018 108.070 0.022
201909 0.054 108.329 0.065
201912 0.009 108.420 0.011
202003 0.009 108.902 0.011
202006 0.010 108.767 0.012
202009 0.010 109.815 0.012
202012 0.007 109.897 0.008
202103 0.007 111.754 0.008
202106 0.012 114.631 0.014
202109 0.012 115.734 0.013
202112 0.010 117.630 0.011
202203 0.010 121.301 0.011
202206 0.010 125.017 0.010
202209 0.010 125.227 0.010
202212 0.009 125.222 0.009
202303 0.009 127.348 0.009
202306 0.009 128.729 0.009
202309 0.009 129.860 0.009
202312 0.007 129.419 0.007

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Can Fite Biofarma  (OTCPK:CFBFF) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Can Fite Biofarma Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Can Fite Biofarma (Can Fite Biofarma) Business Description

Traded in Other Exchanges
Address
10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778
Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Can Fite Biofarma (Can Fite Biofarma) Headlines

From GuruFocus

Can-Fite BioPharma Announces $6 Million Registered Direct Offering

By Marketwired Marketwired 05-20-2019